Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Inclusion Criteria:

1. Male/female participants who are at least 18 years of age on the day of signinginformed consent with histologically confirmed diagnosis of [Stage II, IIIA orIIIB(N2) NSCLC (AJCC Version 8)] will be enrolled in this study. Note: mixed cellularity tumors are allowed. tumor should be considered resectable interms of surgeon's determinations before study entry by investigators. Lymph nodesdisease are recommended to have pathological confirmation. A PET-CT may be utilizedas a surrogate for pathologic staging by site's feasibility.

2. Male participants: A male participant must agree to use a contraception as detailed in Appendix 3 ofthis protocol during the treatment period and for at least 1 year after the lastdose of study treatment and refrain from donating sperm during this period.

3. Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:

4. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR

5. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 duringthe treatment period and for at least [180 days after the last dose ofcarboplatin and for at least 120 days after the last dose of pembrolizumab,whichever occurs latest].

6. The participant (or legally acceptable representative if applicable) provideswritten informed consent for the trial and may also provide consent for futurebiomedical research.

7. Have measurable disease based on RECIST 1.1. Lesions situated in a previouslyirradiated area are considered measurable if progression has been demonstrated insuch lesions. Participants suspected with secondary lung cancer (eg. ground glassnodules) were also eligible for this study (For solid nodules, biopsy, if available,should be performed in case of any intrapulmonary metastasis).

8. Archival tumor tissue sample or newly obtained [core, incisional or excisional]biopsy of a tumor lesion not previously irradiated has been provided.Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.Newly obtained biopsies are preferred to archived tissue.

9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.Evaluation of ECOG is to be performed within 7 days prior to the first dose of studyintervention.

10. Have adequate organ function as defined in the following table. Specimens must becollected within 10 days prior to the start of study intervention.

Exclusion Criteria:

1. Have confirmed sensitizing EGFR mutation or ALK alterations. Note: EGFR and ALKtesting will be performed in local hospital, and do not need to be sent to thecentral laboratory.

2. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment (see Appendix 3). If the urine test is positive or cannot be confirmed as negative,a serum pregnancy test will be required. Note: in the event that 72 hours have elapsed between the screening pregnancy testand the first dose of study treatment, another pregnancy test (urine or serum) mustbe performed and must be negative in order for subject to start receiving studymedication.

3. Has one of the following tumor locations/types:

• NSCLC involving the superior sulcus

• Large cell neuro-endocrine cancer

• Sarcomatoid tumor

4. Has had an allogenic tissue/solid organ transplant.

5. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent orwith an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg,CTLA-4, OX 40, CD137).

6. Has received prior systemic anti-cancer therapy including investigational agents forthe current malignancy prior to [allocation].

7. Has received prior radiotherapy within 2 weeks of start of study intervention orradiation-related toxicities requiring corticosteroids.

8. Has received a live vaccine or live-attenuated vaccine within 30 days before thefirst dose of study intervention. Administration of killed vaccines is allowed. Note: please refer to Section 5.5.2 for information on COVID-19 vaccines

9. Has received an investigational agent or has used an investigational device within 4weeks prior to study intervention administration.

10. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form ofimmunosuppressive therapy within 7 days prior to the first dose of study drug.

11. Known additional malignancy that is progressing or has required active treatmentwithin the past 5 years. Note: Participants with basal cell carcinoma of the skin,squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma insitu of the bladder, that have undergone potentially curative therapy are notexcluded.

12. Has a known severe hypersensitivity (≥Grade 3) to any of the study chemotherapyagents and/or to any of their excipients.

13. Has active autoimmune disease that has required systemic treatment in the past 2years except replacement therapy (eg., thyroxine, insulin, or physiologiccorticosteroid)

14. Has a history of (non-infectious) pneumonitis/interstitial lung disease thatrequired steroids or has current pneumonitis/interstitial lung disease.

15. Has an active infection requiring systemic therapy.

16. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIVtesting is required unless mandated by local health authority.

17. Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA)and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA)infection. Note: Hepatitis B and C screening tests are not required unless:

• Known history of HBV and HCV infection

• As mandated by local health authority

18. Has a history or current evidence of any condition, therapy, or laboratoryabnormality or other circumstance that might confound the results of the study,interfere with the participant's participation for the full duration of the study,such that it is not in the best interest of the participant to participate, in theopinion of the treating investigator.

19. Has known psychiatric or substance abuse disorders that would interfere withcooperation with the requirements of the trial.

20. Is pregnant or breastfeeding or expecting to conceive or father children within theprojected duration of the study, starting with the screening visit through 120 daysafter the last dose of trial treatment.

21. Participants who have had major surgery within 14 days of first treatment.